39740-30-2

Basic information

• Product Name: L-DOPA Ethyl Ester Hydrochloride
• Synonyms: L-DOPA Ethyl Ester Hydrochloride;3,4-Dihydroxy-L-phenylalanine Ethyl Ester Hydrochloride;3-Hydroxy-L-tyrosine Ethyl Ester Hydrochloride;Levodopa Ethyl Ester Hydrochloride;O-Ethyl-DOPA Hydrochloride;3-hydroxy- L-Tyrosine ethyl ester, hydrochloride (1:1)
• CAS NO: 39740-30-2
• Molecular Formula: C₁₁H₁₅NO₄*ClH
• Molecular Weight: 261.70204
• Product Categories: Amino Acids & Derivatives;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Amino Acids & Derivatives, Aromatics, Chiral Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 39740-30-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 51-54°C
• Appearance: /
• Storage Temp.: Hygroscopic, Refrigerator, Under Inert Atmosphere
• Solubility: Methanol, Water
• Stability: Hygroscopic
• CAS DataBase Reference: L-DOPA Ethyl Ester Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: L-DOPA Ethyl Ester Hydrochloride(39740-30-2)
• EPA Substance Registry System: L-DOPA Ethyl Ester Hydrochloride(39740-30-2)

Safety Data

• Hazardous Substances Data: 39740-30-2(Hazardous Substances Data)

Usage

Description

L-DOPA Ethyl Ester Hydrochloride, also known as Levodopa Ethylester Hydrochloride, is a pharmaceutical compound derived from the naturally occurring amino acid L-DOPA. It is an off-white solid with chemical properties that make it a viable candidate for use in the medical field, particularly in the treatment of neurological disorders.

Uses

Used in Pharmaceutical Industry:
L-DOPA Ethyl Ester Hydrochloride is used as an active ingredient for the treatment of Parkinson's disease. It serves as a precursor to dopamine in the brain, helping to alleviate the symptoms of the disease by increasing the levels of dopamine, which is often deficient in Parkinson's patients.
L-DOPA Ethyl Ester Hydrochloride's off-white solid form and chemical properties make it suitable for formulation into various dosage forms, such as tablets or capsules, for easy administration to patients. Its role in Parkinson's disease treatment highlights its importance in the pharmaceutical industry as a key component in managing the condition.

Upstream product

• 64-17-5 ethanol 
• 59-92-7 3,4-dihydroxy-L-phenylalanine 
• 59-92-7 levodopa 

Downstream Products

• 128217-75-4 3-(4,5-Bis-benzyloxy-2-nitro-phenyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionic acid ethyl ester 
• 128217-73-2 2-Allyloxycarbonylamino-3-(4,5-bis-benzyloxy-2-nitro-phenyl)-propionic acid ethyl ester 
• 128217-67-4 3-(3,4-Bis-benzyloxy-phenyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionic acid ethyl ester 
• 69344-36-1 3-(3,4-Bis-benzyloxy-phenyl)-2-tert-butoxycarbonylamino-propionic acid ethyl ester 
• 128217-63-0 2-Allyloxycarbonylamino-3-(3,4-bis-benzyloxy-phenyl)-propionic acid ethyl ester 
• 128217-85-6 2-(6,7-Bis-benzyloxy-2-oxo-1,2,3,4-tetrahydro-quinolin-3-yl)-isoindole-1,3-dione 
• 128217-83-4 (6,7-Bis-benzyloxy-2-oxo-1,2,3,4-tetrahydro-quinolin-3-yl)-carbamic acid allyl ester 
• 128217-76-5 2-Allyloxycarbonylamino-3-(4,5-dimethoxy-2-nitro-phenyl)-propionic acid ethyl ester 
• 69295-27-8 2-Amino-3-(3,4-bis-benzyloxy-phenyl)-propionic acid ethyl ester 
• 128217-65-2 2-Allyloxycarbonylamino-3-(3,4-dimethoxy-phenyl)-propionic acid ethyl ester 
• 128217-61-8 2-tert-Butoxycarbonylamino-3-(3,4-dimethoxy-phenyl)-propionic acid ethyl ester 
• 3165-57-9 2-Amino-3-(3,4-dimethoxy-phenyl)-propionic acid ethyl ester 
• 128218-22-4 C₄₈H₅₁N₃O₁₁ 
• 128217-89-0 2-(3-Allyloxycarbonylamino-6,7-bis-benzyloxy-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyric acid tert-butyl ester 

Relevant articles and documents

NOVEL HIGH PENETRATION DRUGS AND COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON'S DISEASE

PROBLEM TO BE SOLVED: To provide novel high penetration compositions (HPCs) or high penetration prodrugs (HPPs) for treatment of Parkinson's disease. SOLUTION: The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after c

Convenient synthesis of diaryliodonium salts for the production of [18F]F-DOPA

[18F]F-DOPA is an important radiotracer that is used in the diagnosis of Parkinson's disease and neuroendocrine tumours. We describe a simple synthesis for a number of diaryliodonium salt precursors that are suitable for the production of [18F]F-DOPA through reaction with no carrier added (n.c.a.) nucleophilic [18F]fluoride. The simple procedure gives bench-stable, complex iodonium precursors in good yields without the need for laborious anhydrous conditions. Further alteration to the precursor counterion can be readily achieved for a range of halides and pseudo halides by a simple modification of the workup. Preliminary "hot" and "cold" fluorination results show the suitability of the compounds for the production of [18F]F-DOPA.

Fluorination of an arylboronic ester using [18F]selectfluor bis(triflate): Application to 6-[18F]fluoro-l-DOPA

The Ag-mediated electrophilic [18F]fluorination of an arylboronic ester is reported. This new radiochemical transformation uses [ 18F]selectfluor bis(triflate) in acetone. The process gave 6-[ 18F]fluoro-l-DOPA with a RCY of 19 ± 12% and a specific activity of 2.6 ± 0.3 GBq μmol-1.